Drug Profile
MS 553
Alternative Names: MS-553Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Jiangsu MingSight-Relin Pharmaceutical; MingSight Pharmaceuticals
- Class Antineoplastics; Eye disorder therapies
- Mechanism of Action Protein kinase C beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- No development reported Diabetic macular oedema; Diabetic retinopathy
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Diabetic-macular-oedema in China (PO)
- 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Chronic lymphocytic leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Pharmacodynamics data in Chronic lymphocytic leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)